IL163613A0 - Partial and full agonists of a1 adenosine receptors - Google Patents

Partial and full agonists of a1 adenosine receptors

Info

Publication number
IL163613A0
IL163613A0 IL16361303A IL16361303A IL163613A0 IL 163613 A0 IL163613 A0 IL 163613A0 IL 16361303 A IL16361303 A IL 16361303A IL 16361303 A IL16361303 A IL 16361303A IL 163613 A0 IL163613 A0 IL 163613A0
Authority
IL
Israel
Prior art keywords
partial
adenosine receptors
full agonists
agonists
full
Prior art date
Application number
IL16361303A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of IL163613A0 publication Critical patent/IL163613A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL16361303A 2002-02-19 2003-02-19 Partial and full agonists of a1 adenosine receptors IL163613A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35796102P 2002-02-19 2002-02-19
PCT/US2003/007289 WO2003070739A1 (en) 2002-02-19 2003-02-19 Partial and full agonists of a1 adenosine receptors

Publications (1)

Publication Number Publication Date
IL163613A0 true IL163613A0 (en) 2005-12-18

Family

ID=27757687

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16361303A IL163613A0 (en) 2002-02-19 2003-02-19 Partial and full agonists of a1 adenosine receptors
IL163613A IL163613A (en) 2002-02-19 2004-08-19 Partial or full agonists of a1 adenosine receptors and pharmaceutical compositions comprising the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL163613A IL163613A (en) 2002-02-19 2004-08-19 Partial or full agonists of a1 adenosine receptors and pharmaceutical compositions comprising the same

Country Status (15)

Country Link
US (3) US7144871B2 (xx)
EP (2) EP1476455A1 (xx)
JP (1) JP2005527502A (xx)
KR (2) KR20040084929A (xx)
CN (2) CN1636009A (xx)
AU (2) AU2003223237C1 (xx)
CA (1) CA2476683C (xx)
IL (2) IL163613A0 (xx)
MX (1) MXPA04008008A (xx)
NO (1) NO330243B1 (xx)
NZ (1) NZ534801A (xx)
PL (1) PL372145A1 (xx)
RU (1) RU2317994C2 (xx)
WO (1) WO2003070739A1 (xx)
ZA (1) ZA200406607B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
IL163613A0 (en) * 2002-02-19 2005-12-18 Cv Therapeutics Inc Partial and full agonists of a1 adenosine receptors
DE102004032651A1 (de) * 2004-07-06 2006-02-16 Bayer Healthcare Ag Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
US7271157B2 (en) * 2004-07-12 2007-09-18 Cv Therapeutics, Inc. A1 adenosine receptor agonists
RU2443708C2 (ru) * 2007-05-17 2012-02-27 Си Ви Терапьютикс, Инк. Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций
WO2012012736A2 (en) * 2010-07-23 2012-01-26 The Ohio State University Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway
JP2015172077A (ja) * 2015-06-24 2015-10-01 中国医学科学院葯物研究所 Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
EP3426664B1 (en) 2016-03-10 2021-06-30 Janssen Pharmaceutica NV Substituted nucleoside analogues for use as prmt5 inhibitors
JP6909799B2 (ja) 2016-03-10 2021-07-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための置換ヌクレオシドアナログ
EP3512857B1 (en) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
EP3512858B1 (en) 2016-09-14 2023-11-08 Janssen Pharmaceutica NV Fused bicyclic inhibitors of menin-mll interaction
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MX2019003843A (es) 2016-10-03 2019-06-24 Janssen Pharmaceutica Nv Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5.
US10745409B2 (en) 2016-12-15 2020-08-18 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
ES2971035T3 (es) 2017-02-27 2024-06-03 Janssen Pharmaceutica Nv Uso de biomarcadores en la identificación de pacientes con cáncer que mostrarán respuesta al tratamiento con un inhibidor de prmt5
JP7352544B2 (ja) 2017-12-08 2023-09-28 ヤンセン ファーマシューティカ エヌ．ベー． 新規なスピロ二環式類似体
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
US10421734B1 (en) * 2018-08-31 2019-09-24 Sami Labs Limited Process for the preparation of enantiopure 3-amino tetrahydrofuran and its salts
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
WO2020249663A1 (en) 2019-06-12 2020-12-17 Janssen Pharmaceutica Nv Novel spirobicyclic intermediates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
AU4138601A (en) * 1999-12-03 2001-06-12 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
IL163613A0 (en) * 2002-02-19 2005-12-18 Cv Therapeutics Inc Partial and full agonists of a1 adenosine receptors

Also Published As

Publication number Publication date
NO330243B1 (no) 2011-03-14
US7696181B2 (en) 2010-04-13
NO20043907L (no) 2004-09-17
US20090325896A1 (en) 2009-12-31
AU2003223237A1 (en) 2003-09-09
RU2317994C2 (ru) 2008-02-27
US20060287275A1 (en) 2006-12-21
US7144871B2 (en) 2006-12-05
AU2008249143A1 (en) 2008-12-11
KR20100046058A (ko) 2010-05-04
PL372145A1 (en) 2005-07-11
CN101392012A (zh) 2009-03-25
IL163613A (en) 2010-12-30
KR20040084929A (ko) 2004-10-06
CA2476683C (en) 2011-11-01
AU2003223237C1 (en) 2009-03-26
MXPA04008008A (es) 2005-03-23
KR101032005B1 (ko) 2011-05-02
ZA200406607B (en) 2006-05-31
JP2005527502A (ja) 2005-09-15
RU2004125492A (ru) 2006-01-27
AU2008249143B2 (en) 2011-08-25
NZ534801A (en) 2006-04-28
AU2003223237B2 (en) 2008-08-21
US20030232783A1 (en) 2003-12-18
CA2476683A1 (en) 2003-08-28
WO2003070739A1 (en) 2003-08-28
EP2412716A1 (en) 2012-02-01
EP1476455A1 (en) 2004-11-17
CN1636009A (zh) 2005-07-06

Similar Documents

Publication Publication Date Title
IL163613A0 (en) Partial and full agonists of a1 adenosine receptors
HK1210032A1 (en) Compositions and methods of delivery of pharmacological agents
IL165280A (en) 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2b and alpha-2c adrenergic receptors
AU2003273300A8 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
AU2003275128A8 (en) Isolation and use of ryanodine receptors
PT1379504E (pt) Derivados bipiperidinilo e sua utilização como inibidores de receptores de quimioquinas
EP1490373A4 (en) INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES
EP1482895A4 (en) AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
PT1585548T (pt) Composições e métodos de administração de agentes farmacológicos
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
HK1079518A1 (en) Quinazolinone derivatives and their use as cb agonists
AU2003238597A8 (en) Benzimidazole compounds and their use as estrogen agonists/antagonists
AU2003219914A8 (en) Intranasal administration of mc4-r agonists
EP1482896A4 (en) AMINOALKYLPHOSPHONATES AND ASSOCIATED COMPOUNDS AS EDG RECEPTOR AGONISTS
EP1556347A4 (en) GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE
IL196384A0 (en) Corticotropin releasing factor 2 receptor agonists
IL173521A0 (en) Substituted 2 - carbonylamino - 6 piperidinaminopyidines and substituted 1 - carbonylamino - 3 - piperidinaminobenzenes as 5 - th1f agonists
AU2003223653A1 (en) Partial and full agonists of a1 adenosine receptors
IL174056A0 (en) Novel adenosine a3 receptor agonists
AU2003294716A8 (en) Detectable labeled nucleoside analogs and methods of use thereof
AU2003301216A8 (en) Novel use of liver x receptor agonists
HUP0303533A3 (en) Adenosine a1 agonist adenosine derivatives
AU2003260072A8 (en) Antagonists of chemokine receptors
EP1545601A4 (en) ANTIBODIES OF THE LFA-1 ALPHA SUB-UNIT AND METHOD OF USE
HUP0402540A3 (en) Pharmaceutical combinations of adenosine a-2a and betha-2-adrenergic receptor agonists